GTCR Co-Invest XI LP's Form 4 filing
Maravai Lifesciences Holdings, Inc. (MRVI) · filed May 30, 2024
- Accession no.
- 0000950170-24-066799
- Filed
- May 30, 2024, 5:39 PM ET
- Trade date
- May 28, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $97.6M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| GTCR Co-Invest XI LPCIK 0001591432 | Director, 10% Owner |
| GTCR Fund XI/B LPCIK 0001591435 | Director, 10% Owner |
| GTCR Fund XI/C LPCIK 0001591436 | Director, 10% Owner |
| GTCR Partners XI/B LPCIK 0001827959 | Director, 10% Owner |
| GTCR Investment XI LLCCIK 0001827977 | Director, 10% Owner |
| GTCR Partners XI/A&C LPCIK 0001828028 | Director, 10% Owner |
| Maravai Life Sciences Holdings 2, LLCCIK 0001832794 | Director, 10% Owner |
| Maravai Life Sciences Holdings, LLCCIK 0001833157 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 28, 2024 | Class B common stock | DReturned to the companyDisposed | −8,409,946 | –F1 | – | 110,684,080 | Indirect | |
| May 28, 2024 | Class A common stock | CConversionAcquired | +8,409,946 | –F1 | – | 30,090,979 | Indirect | |
| May 28, 2024 | Class A common stock | SSaleDisposed | −9,940,974 | $9.82 | −$97,570,659.81 | 20,150,005 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 28, 2024 | Class A common stock | CConversionDisposed | −8,409,946 | –F1 | – | 110,684,080 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value $0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value $0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.
Referenced by the price of 2 transactions in Table I and 1 transaction in Table II.
Remarks
Each of the reporting persons is a director-by-deputization solely for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.